http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20100008049-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5523a6596f3f408303a7c44014191d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4aaf127397fd5f114d8bfee1628e155e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-351 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-351 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 |
| filingDate | 2008-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fdcb8b5b50b0f63fc54e5b0be055e1e1 |
| publicationDate | 2010-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20100008049-A |
| titleOfInvention | Pharmaceutical composition for treating Parkinson's disease comprising acetylsalicylic acid maltol ester (AME) |
| abstract | Provided is a pharmaceutical composition for treating Parkinson's disease comprising acetylsalicylic acid maltol ester [3- (2-methyl-4-pyronyl) -2-acetyloxybenzoate, AME] synthesized by esterification of acetylsalicylic acid and maltol do. AME is a compound that exhibits antithrombotic and antioxidant effects with negligible gastrointestinal damage. Applicants have shown that AME enhances the expression and activation of GPx, which inhibits PKC, which contributes to MA- and MPTP-induced dopaminergic neurotoxicity leading to Parkinson's disease-like conditions, thereby showing that the AME exhibits anti-Parkinson's effect. Proved to be possible. Therefore, the pharmaceutical composition of the present invention can exert an effective anti-Parkinson's effect by the AME contained in the composition. |
| priorityDate | 2008-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 786.